Emerging Company Profile

Aulos: Tackling the IL-2 space with computational biology

Emerging Company Profile: Aulos believes its computationally designed mAb will stand out in IL-2

Apple Tree-backed Aulos believe its computationally designed mAb will stand out in the IL-2 crowd.

Apple Tree Partners launched Aulos into the crowded IL-2 space last week with a $40 million series A round and a computationally designed IL-2-binding antibody it thinks could